Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway

Jian-Guo Ren, Pankaj Seth, Huihui Ye, Kun Guo, Jun-ichi Hanai, Zaheed Husain & Vikas P. Sukhatme

In this study we have tested the efficacy of citrate therapy in various cancer models. We found that citrate administration inhibited A549 lung cancer growth and additional benefit accrued in combination with cisplatin. Interestingly, citrate regressed Ras-driven lung tumors. Further studies indicated that citrate induced tumor cell differentiation. Additionally, citrate treated tumor samples showed significantly higher infiltrating T-cells and increased blood levels of numerous cytokines. Moreover, we found that citrate inhibited IGF-1R phosphorylation. In vitro studies suggested that citrate treatment inhibited AKT phosphorylation, activated PTEN and increased expression of p-eIF2a. We also found that p-eIF2a was decreased when PTEN was depleted. These data suggest that citrate acts on the IGF-1R-AKT-PTEN-eIF2a pathway. Additionally, metabolic profiling suggested that both glycolysis and the tricarboxylic acid cycle were suppressed in a similar manner in vitro in tumor cells and in vivo but only in tumor tissue. We reproduced many of these observations in an inducible Her2/Neu-driven breast cancer model and in syngeneic pancreatic tumor (Pan02) xenografts. Our data suggests that citrate can inhibit tumor growth in diverse tumor types and via multiple mechanisms. Dietary supplementation with citrate may be beneficial as a cancer therapy.

Citrate is an intermediate in the TCA cycle and an essential donor for protein acetylation. Several lines of evidence suggest that citrate may play a role in cancer biology and reduced concentration of citrate in cancer cells may be related to tumor aggressiveness. Citrate exhibits negative feedback on glycolysis and on the enzyme pyruvate dehydrogenase. Our previously published data demonstrated that depletion of ATP-citrate-lyase (ACL) repressed A549 lung cancer cell proliferation in vitro and growth in vivo, and that this was accompanied by citrate accumulation, suggesting a potential antitumor function for citrate. Similar results have been observed in prostate cancer. In vitro, several studies found that citrate reduced proliferation in multiple tumor cell lines. Loss of citrate synthase led to dramatically upregulated glycolysis, decreased citrate production and accelerated tumor growth and metastases. Oral administration of citrate in two patients has been reported to have an anti-tumor effect, possibly through suppression of glycolysis.

When we began these studies, there was no data on the effects of citrate on tumor growth in animal models. Very recently, a report has been published on the effects of citrate in a gastric cancer model. Here, we report on the therapeutic effects of citrate using diverse xenograft and genetically modified mouse (GEM) models and explore mechanisms of citrate action.

Results

Citrate Inhibits Tumor Cell Proliferation In Multiple Tumor Lines. We first tested whether we could reproduce the findings that citrate could inhibit tumor cell proliferation. As shown in Figure S1, citrate significantly inhibited proliferation (Figure S1A–C) and induced cell death (Figure S1D) in lung cancer A549, breast
citrate treatment significantly suppressed tumor growth at four weeks compared to the control group.

Cisplatin is commonly used for non-small cell lung cancer (NSCLC) treatment. Cisplatin treatment has been shown to increase the sensitivity of A549 cells to cisplatin treatment in vitro. To test whether this observation is valid in vivo, we examined the treatment effect of cisplatin on A549 tumor growth with or without citrate treatment. As shown in Fig. 1B, both citrate and cisplatin inhibited A549 xenograft tumor growth individually. Cisplatin treatment along with citrate slowed tumor growth even more.

To begin to probe the underlying biological mechanisms, we asked whether citrate treatment led to cell differentiation in A549 cells. Indeed, this appeared to be the case as evidenced by increased E-cadherin expression (Fig. 1C) and reduced snail expression (Fig. 1D) in vitro. In A549 xenografts, we observed cisplatin-induced tumor differentiation with glandular structure formation compared to the diffuse tumor growth pattern in controls (Fig. 1E). Furthermore, while citrate and cisplatin increased E-cadherin expression individually, their combination showed a markedly enhanced effect (Fig. 1F, top panel).

MUC-1 overexpression is associated with poor prognosis in NSCLC and confers resistance to anticancer agents. In A549 xenografts, MUC-1 expression in tumor cells was inhibited by citrate and cisplatin treatment individually, and the combination of citrate and cisplatin further reduced MUC-1 expression (Fig. 1E, bottom panel).

Citrate Suppresses Tumor Growth In A Lung Cancer GEM Model. Although xenograft models are widely used for cancer studies, the nude mice used in these studies are immunodeficient. Therefore, we used a GEM model of Ras-driven lung tumorigenesis to study the effects of citrate on tumor growth. Mice with Ras-driven tumors were treated with a total of 4g/kg/day of citrate (administered twice a day by gavage) for 7 weeks. As shown in Fig. 2A and B, citrate treatment resulted in a significant reduction in area occupied by tumor nodules (P < 0.001). Consistent with our findings in cell lines and xenografts, citrate induced tumor differentiation in the GEM model as indicated by increased E-cadherin expression (Fig. 2C). Surprisingly, tumor growth suppression in the Ras-driven lung tumor model was more significant than that in the A549 xenograft model, also known to be driven by mutated Ras. Indeed, computerized tomography (CT) scans performed before and after citrate treatment for 7 weeks showed significant tumor shrinkage (Fig. 2D and E). Importantly, at the doses used, there was no evidence of citrate induced tissue toxicity in major organs in the Ras model by histology or function (Figure S3A and Tables S1 and S2). Citrate levels measured in plasma of these chronically citrate treated animals are shown in Figure S3B and are approximately 3 mM, roughly 8 times those noted in non-citrate treated animals.

To test whether citrate-mediated tumor suppression extends to other tumor types, we examined the effect of citrate on the growth of breast tumors in a Her2/Neu-driven GEM model. Citrate treatment significantly reduced breast tumor growth (Figures 4A and B), increased E-cadherin expression (Figure 4C), and appeared to induce tumor differentiation as indicated by tubule formation (Figure 4D). Additionally, citrate activated caspase-8 in vivo (Figure 4E), consistent with similar in vitro data. Besides the growth inhibitory effect of citrate on lung and breast tumors in vivo, we also found that citrate administration in drinking water markedly suppressed pancreatic tumor growth (Pan02 cells grown subcutaneously) (Figure 4F). No evidence of toxicity in the liver or lung was noted in the Her2/Neu model with citrate treatment (Figure 5).

Citrate Promotes Tumor-Infiltrating Leukocytes. We noted that tumors in our two genetic models, as compared to xenografts, were more sensitive to citrate treatment. Genetic tumor models have intact immune systems. Citrate metabolism has been reported to play a critical role in lipopolysaccharide (LPS) signaling. Therefore, we asked whether citrate might enhance antitumor immune response. To test this hypothesis, we examined tumor-infiltrating lymphocytes in citrate treated tumor tissue. As shown in Fig. 3 (top panel), in the Ras driven lung tumor model, citrate treated tumors had abundant leukocyte infiltration, as demonstrated by labeling with anti-CD45 antibody. These cells were predominantly T lymphocytes as they were CD3 positive (Fig. 3, bottom panel). Similar results were observed in the Her2/Neu driven breast tumors (Figure S6).

Citrate Enhances Pro-Inflammatory Cytokine Secretion. We asked whether citrate treatment induced secretion of cytokine IL-1β by macrophages in vitro, since acute IL-1β secretion regulates immune
Figure 1. Citrate suppresses tumor growth in vivo. The effects of citrate on tumor growth were examined in xenograft and genetic tumor models. (A) $5 \times 10^6$ A549 cells were injected into nude mice. When the tumor volume reached about 100 mm$^3$, mice were given 4 g/kg citrate twice a day for 4 weeks, and tumor-bearing mice were sacrificed after 6 weeks. (B) A549 xenograft tumors were treated with citrate (twice daily from day 14 to 40), cisplatin or citrate/cisplatin combination (3 doses of cisplatin at 4 mg/kg on days 14, 17 and 20 were given by i.p.). Tumor volume was calculated using the formula: $V = 0.4 AB^2$ (A: long diameter; B: short diameter). (C) A549 cells were treated with citrate for 72 h and cell lysate was analyzed by western blot with E-Cadherin and β-tubulin antibodies. The full-length blots are presented in Supplemental Figure S11. (D) A549 cells were treated with citrate for 72 h and cell lysate was analyzed by western blot with Snail and β-tubulin antibodies. The full-length blots are presented in Supplemental Figure S12. (E) Citrate treatment induces A549 xenograft tumor differentiation (tumor sections from experiment in panel A). $5 \times 10^6$ A549 cells were injected into nude mice. Tumor-bearing mice were sacrificed after 6 weeks of treatment and the tumors were dissected and fixed with 4% PBS-balanced PFA and samples were embedded with OCT. E-cadherin and Muc-1 expression was assessed following standard immunofluorescence protocol. DAPI counter staining shows cell nuclei.
response and suppresses tumor growth\(^2\), although chronic IL-1\(\beta\) secretion contributes to tumor development\(^2\).

We treated macrophages (derived from THP1 cells through PMA induction) with citrate and analyzed IL-1\(\beta\) secretion. As shown in Fig. 4A, citrate induced IL-1\(\beta\) secretion in a dose-dependent manner. Next, we asked whether citrate promotes cytokine secretion \textit{in vivo}. We treated Ras-driven lung tumor mice for 7 weeks with 4g/kg citrate and analyzed cytokine profiles in the plasma. As shown in Fig. 4B, 7-week citrate treatment induced the secretion of most cytokines examined, from several fold to several hundred fold. We then examined whether citrate induced cytokines acutely \textit{in vivo}. We found that many cytokines increased within 30 min of treatment (Fig. 4C), suggesting cytokine pan-activation. The cytokine pattern for the chronic data was somewhat similar to the acute data but more accentuated. Our data suggest that both pro-inflammatory cytokines (e.g. interleukin-1, tumor necrosis factor-alpha, etc) and anti-inflammatory cytokines (e.g. interleukin-10 and interleukin 1 receptor antagonist) are activated in citrate treated plasma. There was no evidence of Th1 vs Th2 skewing. These results suggest that citrate can rapidly enhance cytokine secretion and that these effects may persist to potentially modulate immune responses \textit{in vivo}.

**Citrate Inhibits IGF-1R Activation And Its Downstream Pathway.** To uncover intracellular signaling pathways impacted by citrate treatment, we screened tyrosine kinases targets in A549 cells. As shown in Fig. 5A, tyrosine kinase screening revealed that IGF-1R phosphorylation was significantly reduced in citrate treated cells. To validate this finding, we immunoprecipitated IGF-1R in citrate treated A549 and blotted with anti-p-IGF-1R antibody. Our results confirmed that citrate inhibited IGF-1R phosphorylation in this cell line (Fig. 5B), though this was accompanied by a decrease in total IGF-1R expression. Also, reduced AKT phosphorylation was noted (Fig. 5C). Citrate effects on IGF-1R and AKT phosphorylation were also observed in MCF-7 and BxPC3 cells (Figure S7A), although in these cells, total IGF-1R was unchanged. Curiously, AKT phosphorylation was also diminished by citrate treatment in normal lung primary (NLP) cells (Fig. 5C). To examine whether

---

**Figure 2.** Citrate inhibits Ras driven mouse lung tumor growth in a genetic model. Ras G12D mice with lung tumor were treated with 4g/kg citrate twice a day for 7 weeks. (A and B) Citrate treatment affects Ras G12D mouse lung morphology (A) and represses tumor growth (B). (C) Citrate induces Ras-driven lung tumor differentiation as indicated by E-cadherin expression. Samples were collected and stained with anti-E-cadherin antibody. (D): CT scans on a representative Ras-driven lung tumor before and after citrate treatment. (E) Quantitative analysis of lung tumor growth, plotted as percentage change in tumor volume (Control: n = 3; Citrate: n = 4).

---
citrate treatment inhibits IGF-1R phosphorylation in vivo, we stained for p-IGF-1R in sections of citrated treated Ras driven lung tumors. As shown in Fig. 5D, citrate inhibited IGF-1R phosphorylation in tumor cells. Similar data was obtained in the Her2/Neu driven breast tumor model (Figure S7B). Durfort et al. reported that knock-down of IGF-1R increased the infiltration of lymphocytes and polymorphonuclear neutrophils, and induced secretion of two pro-inflammatory cytokines, TNF-α and IFN-γ. Therefore, we hypothesized that citrate treatment may suppress tumor growth via inhibition of IGF-1R phosphorylation (and activity), which might increase tumor-infiltrating T lymphocytes and pro-inflammatory cytokines.

To begin to address this question, we examined downstream effectors of the IGF-1R pathway. It is known that IGF-1R activates AKT, which in turn can inhibit PTEN through inactivating the PTEN activator FoX3a via phosphorylation, resulting in inhibition of the PTEN downstream effector eIF2α, an ER stress marker, which is involved in modulating immune responses. Since citrate treatment inhibits IGF-1R and AKT phosphorylation, it may lead to accumulation of non-phosphorylated FoX3a, thus activating PTEN and eIF2α. Thus, we examined eIF2α levels in response to citrate treatment. As shown in Fig. 6A, eIF2α activity was increased in A549 cells after citrate treatment. Similarly, PTEN was activated (as judged by expression of p-PTEN) when A549 cells were treated with citrate (Fig. 6B). The same result was seen in THP1 cells (Fig. 6C). Next, we established cells in which PTEN was stably knocked down using the MCF-10A cell line, and assessed the effect of PTEN on eIF2α expression. As shown in Fig. 6D, in cells in which PTEN was constitutively knocked down by shRNA, depletion of PTEN almost completely blocked eIF2α activation. Taken together, the above data suggest that citrate appears to impact the IGF-1R-AKT-PTEN-eIF2α signal transduction pathway.

**Citrate Represses Glycolysis And TCA Cycle In Vitro And In Vivo.** Increased AKT pathway signaling has been shown to correlate with increased rates of glucose metabolism observed in cancer cells compared to normal cells. Conversely, inhibition of glycolysis suppresses tumor growth and can contribute to CD8+ T cell maturation. Therefore, we hypothesized that citrate-mediated AKT inhibition might down regulate glycolysis. To probe whether citrate treatment affects glycolysis (as well as the TCA cycle), we examined oxygen consumption and ROS production in vitro. Figure S8A shows that citrate treatment of A549 cells dramatically reduced oxygen consumption. Consistent with this data, we observed a decrease in ROS in A549 (Figure S8B) and more...
dramatically in WM983B melanoma cells (Figure S9). We also measured extracellular acidification rate (ECAR) and found it to be unchanged (data not shown).

To further explore the effect of citrate treatment on intermediary metabolism, we assessed metabolites both in cell culture and in vivo. As shown in Fig. 7A, all glycolytic intermediates except for fructose-1,6-bisphosphate, 1,3-diphosphoglycerate and pyruvate decreased in a dose responsive manner. These data suggest that two glycolytic enzymes may be inhibited by citrate: aldolase which catalyzes conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate (GLAP) and dihydroxyacetone phosphate, and phosphoglycerate kinase (PGK), which catalyzes conversion of 1,3 diphosphoglycerate to 3-phosphoglycerate. Also, we verified by 13C-glucose labeling experiments that the increase in pyruvate is not originating from glycolysis (data not shown) and this increase was not seen in vivo (see below). Moreover, we analyzed changes in TCA cycle metabolites in A549 cells treated with citrate. Figure 7B indicates that many TCA cycle metabolites were dramatically reduced, including D-isocitrate, α-ketoglutarate, succinate, fumarate and malate. These changes could be due to inhibition of aconitase, which converts cis-aconitate to D-isocitrate. Collectively, our metabolite profiling indicates that glycolysis and the TCA cycle were inhibited by citrate treatment in vitro in A549 cells and is consistent with less oxygen consumption under this condition.

To examine whether these citrate-induced changes also occur in vivo, we analyzed metabolic profiles in animals with Ras-driven lung cancers. As shown in Fig. 7C,D, glycolysis and the TCA cycle in the lung tumors appeared to be inhibited, similar to the data in vitro in A549 cells, in which Ras is known to be mutated. In particular, changes in glycolytic metabolites mirrored those seen in A549 cells, suggesting blocks at aldolase and PGK. Citrate treatment also appeared to dramatically suppress the TCA cycle. As shown in Fig. 7D, TCA cycle metabolites downstream of cis-aconitate were significantly reduced, similar to the A549 data, suggesting aconitase inhibition. Interestingly, in Ras-driven lung tumors, citrate appeared to affect glycolysis and TCA in the liver only minimally (data not shown). Of note, in the Ras-driven lung tumor model, Ras is over-expressed only in lung tissue and this may explain why citrate treatment leads to different metabolite results in the lung and liver.

Figure 4. Citrate treatment enhances cytokines secretion. (A) Citrate induces IL-1β secretion in PMA-induced macrophages. The full-length blots are presented in Supplemental Figure S13. (B) Chronic citrate treatment enhances cytokine secretion in plasma from Ras-driven mice. (C) Acute citrate treatment affects cytokine secretion in plasma from Ras-driven mice. Sup: supernatant; Pell: pellet.
Taken together, our data suggest that citrate may inhibit tumor growth via inhibiting glycolysis and the TCA cycle and that this effect appears to be selective to tumor tissue.

In Her2/Neu driven breast tumors (Figure S10A), the glycolysis data suggests inhibition of PFK1 (rather than aldolase as noted for the lung tumors) and PGK (similar to lung data) and little impact on the TCA cycle (Figure S10B), also in contrast to the lung tumor data. It seems therefore that citrate affects metabolism somewhat differently in Ras and Her2/Neu driven tumors.

Discussion

We report several novel findings: (1) citrate administration inhibits the growth of several tumor types (breast, pancreas, lung) both in transplant and genetically engineered models, (2) citrate treatment regresses tumors in a Ras-driven lung cancer model, (3) citrate induces differentiation in vivo, (4) citrate alters cytokines in blood and causes T-cell infiltration into tumor tissue, (5) citrate impacts IGF-1R phosphorylation and downstream events including phosphorylation of AKT and eIF2α, (6) citrate suppresses glycolysis and the TCA cycle, acting at specific points in these pathways, with effects in vitro and in vivo that roughly parallel each other that may be tumor type dependent, and (7) at the doses used, citrate appears to be non-toxic. Collectively our data point to effects of citrate on immune response, tumor metabolism, and signal transduction pathways.

A major motivation for these studies stemmed from our previous work indicating that depletion of ACL leads to citrate accumulation and A549 cell growth inhibition and differentiation. We therefore hypothesized that administration of citrate in vitro might mimic the ACL knockdown phenotype. Moreover, several studies had suggested that citrate inhibits tumor cell proliferation and induces apoptosis in vitro in multiple cell types. Also, Lin, CC et al. found that loss of citrate synthase resulted in markedly unregulated glycolysis, decreased citrate production and accelerated tumor malignancy. Interestingly, citrate concentration in human seminal fluid from prostate cancer patient is 2.7 folds lower than normal patients. Giskeodegard, G.F. et al. studied the metabolic...
Figure 6. Citrate treatment induces eIF2α expression and activates PTEN pathway. Cells treated with or without citrate for 72 hours and equal amount of protein were subjected to SDS-PAGE. (A) Citrate treatment increases e-IF2α activity. The full-length blots are presented in Supplemental Figure S16. (B) Citrate treatment increases the active form of PTEN activity in A549 cells. The full-length blots are presented in Supplemental Figure S17. (C) Citrate treatment increases the active form of PTEN in a macrophage (THP1) cells. The full-length blots are presented in Supplemental Figure S18. (D) Knockdown of PTEN inhibits e-IF2α expression in MCF-10A cells. The full-length blots are presented in Supplemental Figure S19.

Figure 7. Citrate treatment affects glycolysis and TCA in vitro and in vivo. (A) Citrate treatment affects glycolysis in A549 cells. (B) Citrate treatment affects the TCA cycle in A549 cells. (C) Citrate treatment affects glycolysis in Ras G12D mouse lung. (D) Citrate treatment affects the TCA cycle in Ras G12D mouse lung.
profiling of prostate cancer and found that both the concentrations of spermine and citrate decreased in high grade prostate tumor samples as compared with normal tissues. Along with two patient reports cited earlier, these studies suggested that we should explore the efficacy of citrate treatment in various tumor models and probe possible mechanisms of action.

Citrate's effect in several tumor models may be explained by its broad actions on signaling pathways (in particular those involving IGF-1R and its downstream events), intermediary metabolism (both glycolysis and TCA cycles), and immune response (T-cell infiltration and cytokine changes). These multiple mechanisms of action may explain the ability of citrate treatment to regress Ras-transformed tumors. Regression is not often seen with interventions that inhibit a single intermediary metabolic enzyme (one exception is inhibition of LDH-A31; another is IDH-1 in leukemic cells35).

The ability of citrate treatment to promote differentiation and reverse EMT in vivo especially in conjunction with chemotheraphy (as assessed by E-cadherin, vimentin and MUC-1 expression) is also noteworthy. The effects on MUC-1 are especially impressive since a large body of literature suggests that MUC-1 expression is indicative of an aggressive cancer phenotype33, 34.

Our data suggest that part of citrate's efficacy is via the immune system. Citrate can promote a striking increase across a wide range of cytokines, almost reminiscent of a cytokine storm. Disappointingly, there was no clear-cut polarization of the response e.g. a skewing to the Th1 direction. Drugs that might do this might synergize with citrate therapy. Why does citrate display the immune-enhancing function? IGF/IGF-1R plays important and diverse roles in tissue development and function. This pathway is also involved in immune function regulation36. Knockdown IGF-1R delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model37. The number of infiltrating T-cells significantly increased in citrate treated tumor samples, suggesting activation of antitumor adaptive immune response. Current experiments are defining the cell types involved in the immune response, the impact of ablating specific T cell populations and the possibility of combining citrate therapy with other immune interventions such as checkpoint inhibitors. It will also be important to define the effects of citrate on T cell metabolism (glycolysis and TCA cycle), since there could be both beneficial and detrimental effects e.g. Sukumar, M. et al.28 found that augmenting glycolytic flux drives CD8+ T cells toward a terminal differentiated state, while its inhibition preserves the formation of long-lived memory CD8+ T cells.

The IGF-1R pathway appears to plays an important role in tumorigenesis, metastasis and resistance to existing forms of anti-cancer therapy36, 37. Especially in NSCLC and triple-negative breast cancer cell lines, high IGF-1R activity correlates with sensitivity to anti-IGF-1R therapy38, 39. Many preclinical studies targeting the IGF-1R have been shown promising anti-neoplastic activity40 and early phase I41 and phase II42 reports have been encouraging. We found that citrate inhibits IGF-1R activity in vitro and in vivo. The mechanism by which citrate treatment leads to IGF-1R activity inhibition is uncertain. Our data suggested that citrate treatment inhibits both IGF-1R and AKT activity in multiple cell lines. This means that citrate may affect the IGF-1R/AKT signal transduction pathway. Decreased AKT activity could inhibit FoxO3a phosphorylation and lead to FoxO3a accumulation in the nucleus, which can upregulate PTEN43. Our data supports this hypothesis, since we found that citrate treatment increased PTEN activity in A549 cells. eIF2α phosphorylation is important to response to various types of environmental stress and is essential for regulation of translation initiation. Phosphoinositide-3-kinase (PI3K) plays an important role in signal transduction in response to a wide range of cellular stimuli involved in cellular process that promote cell proliferation and survival. The eIF2α phosphorylation pathway is downstream of PTEN, and reconstitution of PTEN-null human glioblastoma or prostate cancer cells with either wild-type PTEN or phosphatase-defective mutants of PTEN induced eIF2α phosphorylation44. It has been shown that deregulation of the eIF2α checkpoint and consequent permissiveness to virus infection may be a common occurrence in tumorigenic mammalian cell lines45. In our system, the phosphorylation of eIF2α dramatically increased when treated with citrate in A549 cells. Knockdown of PTEN in a breast tumor cell line inhibited the phosphorylation of eIF2α. Collectively, our study indicates that citrate treatment activates eIF2α through down regulating the IGF-1R-AKT pathway and up regulating the PTEN-eIF2α pathway.

Citrate is also a key metabolite known to exert a negative feedback on glycolysis via allosteric modulation of PKF1. ATP inhibits the enzyme by decreasing its affinity for fructose-6-phosphate. Citrate enhances the inhibitory effect of ATP4. Our findings are that citrate can impact glycolysis in tumor tissue at different points (PKF1, aldolase, PGK) and that this may depend on the driving mutations and tumor type. Also, our findings suggesting inhibition of aconitase (in the TCA cycle) in the Ras model are novel.

Very recently, Wang et al.16 have reported in vivo data using citrate in a gastric cancer model. They showed decreased glycolysis in vitro and increased apoptosis in vitro and in vivo. Interestingly, they used significantly lower doses of citrate (the maximum dose was 30 mg per kilogram per day) and obtained inhibition of approximately 50% in tumor volume. They noted that PKF1 enzyme activity was inhibited by 60 to 70% in vitro, as suggested by our data in Her2/Neu mice. Curiously, IGF-1R is highly expressed in some gastric cancers and may explain sensitivity of this tumor type to citrate therapy46, 47.

Chronic citrate treatment was non-toxic as evidenced by gross pathology in numerous organs (liver, lung, spleen and kidney) and by plasma electrolytes and liver and kidney function tests. Plasma levels in chronically treated animals were approximately 3 mM and of note, calcium levels were unchanged. Both gavage twice a day and drinking water throughout the day appeared to be effective (total dose 8 g per day), corresponding to approximately 56 g of citrate in a 70 kg person. A phase I study using 0.5 g per kilogram of sodium citrate given orally was well-tolerated48, 49.

Our study has several limitations. We do not know how the exogenously administered citrate is transported into tumor and normal cells and how it affects intracellular citrate and in what cell compartments. Which of the effects of citrate are the most important in affecting tumor biology? Does citrate impact systemic pH as part of its mechanism of action? What appears to give this therapy selectivity for tumor cells? Despite these limitations, our data suggests that clinical studies using citrate to treat a wide variety of cancers are warranted as a non-toxic and affordable treatment.
Materials and Methods

Materials. Dichlorodihydrofluorescein diacetate (CM-H2DCF-DA) was purchased from Invitrogen/Molecular Probes (Carlsbad, CA). Fetal bovine serum (FBS) was obtained from Gibco. The anti-E-cadherin monoclonal antibody was from Santa Cruz Biotechnology. The Caspase-8 and 9, anti-IGF-1R, phospho-IGF-1R, phospho-AKT473, AKT1/2, phospho-AMPKα (T172) and AMPKα polyclonal antibodies were purchased from Cell Signaling Technology. The anti CD3 and anti-CD45 antibodies were from Abcam. Secondary antibodies for enhanced chemiluminescence (ECL) detection were from Amersham Biosciences. Citrate assay kit was obtained from Abcam. Human Phospho-Receptor Tyrosine Kinase Array Kit was purchased from R&D systems. All other reagents were of standard analytical grade.

Cell Culture. The human lung cancer cell line A549, MCF-7, BxPC3, B16F10 and normal human lung epithelial cells were obtained from American Type Culture Collection. WM983B melanoma cells were purchased from the Wistar Institute. A549 cells were grown in Ham's F12 Medium (Cellgro, VA). MCF-7 cells were maintained in DMEM medium. BxPC3 and B16F10 cells were grown in RPMI 1640 medium. All of the above media were supplemented with 10% FBS and 1% penicillin and 100 μg/ml streptomycin, and grown at 37°C and 5% CO2. WM983B melanoma cells were grown in MCDB153 medium and supplemented 20% horse serum and 2% FBS. The normal lung epithelial cells were grown in Ham's F-12 medium plus growth factors. HMLE, HMLER and Snail cells (HMLE cells with constitutive expression of mutated Ras and Snail respectively) were grown in mammary epithelial growth (MEGM) medium (Biowhittacker, Inc., Maryland, MD, USA), a serum-free medium composed of modified MCDB 170 basal medium with supplements) as described before50.

Western Blotting. Cells with and without citrate addition were lysed with RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate), and equal protein amounts were resolved by 4–12% Bis-Tris gels (Invitrogen), as previously described51. Briefly, the proteins were transferred to 100 beads per sample per cytokine. Each sample was measured in duplicate. Plates were read using a Luminex 200 instrument with a lower bound of 5000 beads per sample per cytokine. After 24, 72, 120 and 168 hours of initial plating, 0.5 ml cells were harvested and re-suspended in 100 μl of 1X Nexin buffer and counted by Coulter counter. All samples were assayed in triplicate to generate proliferation curves as described52.

Cytokines Assay. The effect of citrate on plasma cytokines was analyzed by luminex (polystyrene bead kits). Ras-driven lung cancer mice were chronically treated with 4 g/kg citrate (twice a day) for 7 weeks. For certain experiments, 30 min before sacrifice, mice were dosed with citrate and plasma was collected. This assay was performed in the Human Immune Monitoring Center at Stanford University. Mouse 26 plex kits were purchased from Affymetrix and used according to the manufacturer's recommendations with modifications as described below. Briefly, samples were mixed with antibody-linked polystyrene beads on 96-well filter-bottom plates and incubated at room temperature for 2 h followed by overnight incubation at 4°C. Room temperature incubation steps were performed on a orbital shaker at 500–600 rpm. Plates were vacuum filtered and washed twice with wash buffer, then incubated with biotinylated detection antibody for 2 h at room temperature. Samples were then filtered and washed twice as above and resuspended in streptavidin-PE. After incubation for 40 minutes at room temperature, two additional vacuum washes were performed, and the samples resuspended in Reading Buffer. Each sample was measured in duplicate. Plates were read using a Luminex 200 instrument with a lower bound of 100 beads per sample per cytokine.

Proliferation Assay. Control and citrate treated cell were plated in 6-well plate at a density of 1 × 105 cells/well and maintained at 37°C in a 5% CO2 incubator. After 24, 72, 120 and 168 hours of initial plating, 0.5 ml cells were diluted into 10 ml of Hanks' buffer and counted by Coulter counter. All samples were assayed in triplicate to generate proliferation curves as described52.

Annexin-V Apoptosis Assay. Apoptosis was measured by staining with the Nexin reagent using a Nexin kit and counting on the Guava PCA-96 system (Guava Technologies) as per the manufacturer's protocol. Briefly, cells were harvested and re-suspended in 100 μl of 1X Nexin buffer, and then mixed with 100 μl of Annexin-V-PE, and Nexin 7-AAD. The cells were allowed to incubate for 20 minutes at room temperature and analyzed in the Guava flow cytometer.
Determination of Cellular Reactive Oxygen Species (ROS). Intracellular ROS production was measured by staining with CM-H2DCFDA. CM-H2DCFDA is a cell-permeant indicator for ROS that is non-fluorescent until removal of the acetate groups by intracellular esterases and oxidation occurs within the cell. The procedure for measuring ROS was carried out as described earlier, with minor modification. Briefly, A549 cells transduced with shRNA lentiviral particles or control vector were selected with puromycin for 2 weeks, and then incubated with 10 μM CM-H2DCF-DA for 3 hours, followed by flow cytometry using a FACSCalibur equipped with CellQuest Pro software. Superoxide radicals (O$_2^-$) were measured separately using the MitoSOX reagent according to the manufacturer’s protocol (Invitrogen). In brief, cells with or without ME2 knockdown were incubated with 5 μM MitoSOX™ reagent for 10 minutes at 37 °C, then washed three times and observed under a fluorescence microscope using the Rhodamine filter and Axiovision software for capturing images (Zeiss, Germany).

Xenograft Model in Nude Mice. Animal experiments were performed under federal guidelines and approved by the Institutional Animal Care and Use Committee (IACUC) of the Beth Israel Deaconess Medical Center (approval number 0342007). A549 xenografts in nude mice were generated by following the description of Verrax J et al. Briefly, approximately 5 × 10$^6$ A549 cells suspended in 100 μl of a serum-free culture medium were subcutaneously injected into the right and left flanks of female Athymic nude mice, respectively. Tumor-bearing mice were sacrificed after 6–8 weeks and tumor masses were measured or imaged before excision. Tumor lysates were prepared by homogenization of tumor tissues in RIPA lysis buffer and were resolved by SDS-PAGE and transferred onto PVDF membranes and immunoblotted with various antibodies and normalized by β-tubulin as a loading control.

K-RasG12D driven lung tumor. The Ras-driven mouse lung tumor transgenic mice were generated following Fisher, G.H. et al. and housed in pathogen-free conditions and handled in accordance with institutional guidelines. Briefly, bitransgenic mice were produced by crossing the CCSP-tRTA activator mice to Tet-op-K-RasG12D responder mice. All genotyping was done by PCR as described in the literature. Once homozygous K-RasG12D mice were obtained, the mice were switched to tetracycline water and continued to be housed for 1–2 months, and then treated with 4/g/kg citrate twice a day by gavage. In order to monitor tumor volume change, before and after citrate treatment, the tumors in the lung were scanned using micro CT method as described. Briefly, animals were anesthetized with 2% isoflurane/balance O2. Imaging was performed using the CT component of a NanoPET/CT (Bioscan, Washington, DC) scanner equipped with an 8 W X-ray source running at 45kVp (178mA) and a 48 mm pitch CMOS-CCD X-ray detector. Continuous helical micro-CT scanning was employed with the following parameters: 1.6 s exposure, 483 angles, 2.45 magnification, 37 mm pitch (1 field-of-view), and a 512 × 1798 pixel frame size (0.096 mm pixels). Images were reconstructed as 536 × 536 pixel transverse matrices with varying axial length and slice thickness of 0.1mm (isotropic voxel size 0.078 mm) using filtered-back projection (RamLak filtering). Image analysis was performed using VivoQuant software (invivCRO, Boston, MA) using a Hounsfield Unit windowing technique, normalized for all scans. Volumetric segmentation was performed using a neighborhood threshold.

Her2/Neu Driven Mouse Breast Tumor. The Her2/Neu-driven mouse breast tumor transgenic mice were generated as described before. Briefly, transgenic mice were housed in pathogen-free conditions and handled in accordance with institutional guidelines with a 12 hr light/dark cycle and access to food and water ad libitum. Induced animals were administered doxycycline (0.1–2 mg/ml) (Sigma) in their drinking water, which was replaced weekly. Animals were inspected for tumors, and existing tumors were measured weekly and treated with 4/g/kg citrate by gavage twice a day. At the indicated times of sacrifice, animals were killed by CO2 asphyxiation and tissues were either snap-frozen on dry ice for protein analysis, or fixed in 4% paraformaldehyde for morphological and immunohistochemical analysis.

Metabolite Profiling. To determine differences in metabolite profiles between citrate-treated and control cells, metabolite extracts were prepared and then analyzed using liquid chromatography tandem mass spectrometry (LC-MS) as described before.

Tumor Area Measurement And Lung Metastasis Assay. Lungs from mice bearing Ras-driven tumors were removed and washed three times with PBS. Formalin-fixed, paraffin-embedded mouse lung tissue sections were prepared at 5 μm. H&E stained slides were scanned and tumor area were quantified with Image J (NIH software). Microscopic images (40X) of stained tissue sections were collected. Similarly, lung metastatic lesions were counted under a low-power microscope. Statistical significance was analyzed using PRISM software.

Statistical Analysis. All data are expressed as the mean ± s.d. and were analyzed using the two-tailed Student t-test or one-way ANOVA. *P < 0.05 was considered to be significant. **P < 0.01; ***P < 0.001. All tests were performed using the PRISM software (GraphPad Software, Inc., La Jolla, CA).

References
1. Philippe, I. & Hubert, L. The reduced concentration of citrate in cancer cells: An indicator of cancer aggressiveness and a possible therapeutic target. *Drug Resist Updat* **29**, 47–53 (2016).
2. Garland, P. R., Randle, P. J. & Newsholme, E. A. Citrate as an Intermediary in the Inhibition of Phosphofructokinase in Rat Heart Muscle by Fatty Acids, Ketone Bodies, Pyruvate, Diabetes, and Starvation. *Nature* **200**, 169–170 (1963).
3. Taylor, W. M. & Halperin, M. L. Regulation of pyruvate dehydrogenase in muscle. *Inhibition by citrate*. *J Biol Chem* **248**, 6080–6083 (1973).
4. Icard, P., Poullain, L. & Lincet, H. Understanding the central role of citrate in the metabolism of cancer cells. *Biochimica et biophysica acta* 1825, 111–116 (2012).

5. Hillar, M., Lott, V. & Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver mitochondria and submitochondrial particles. *J Bioenerg Bioter* 7, 1–16 (1975).

6. Hanai, J. et al. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. *J Cell Physiol* 227, 1709–1720 (2012).

7. Shah, S. et al. Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism. *Oncotarget* 7, 43713–43730 (2016).

8. Zhang, X. et al. Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin. *Anticancer Res* 29, 1249–1254 (2009).

9. Chen, L. et al. Citrate synthase expression affects tumor phenotype and drug resistance in human ovarian carcinoma. *PLoS One* 9, e115708 (2014).

10. Lincet, H. et al. Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells. *J Ovarian Res* 6, 72 (2013).

11. Lu, Y. et al. Citrate induces apoptotic cell death: a promising way to treat gastric carcinoma? *Anticancer Res* 31, 797–805 (2011).

12. Krupig, B., Niklchian, A., Orrenius, S., Zhivotovsky, B. & Goyvaerts, V. Citrate kills tumor cells through activation of apical caspases. *Cell Mol Life Sci* 69, 4229–4237 (2012).

13. Lin, C. C. et al. Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy. *Sci Rep* 2, 785 (2012).

14. Halabe Bucay, A. Hypothesis proved...citric acid (citrate) does improve cancer: a case of a patient suffering from medullary thyroid cancer. *Med Hypotheses* 73, 271 (2009).

15. Bucay, A. H. Clinical report: a patient with primary peritoneal mesothelioma that has improved after taking citric acid orally. *Clin Hepatol Gastroenterol* 35, 241 (2011).

16. Wang, T. A., Zhang, X. D., Guo, X. Y., Xian, S. L. & Lu, Y. F. 3-bromopyruvate and sodium citrate target glycolysis, suppress survivin, and induce mitochondrial-mediated apoptosis in gastric cancer cells and inhibit gastric orthotopic transplantation tumor growth. *Oncol Rep* 35, 1287–1296 (2016).

17. Bouillez, A. et al. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. *Cancer Res* 76, 1538–1548 (2016).

18. Ham, S. Y. et al. Mucin 1-mediated chemo-resistance in lung cancer cells. *Oncoimmunology* 5, e185 (2016).

19. Infantino, V. et al. The mitochondrial citrate carrier: a new player in inflammation. *The Biochemical Journal* 438, 433–436 (2011).

20. O'Neill, L. A. A critical role for citrate metabolism in LPS stimulated adipocytes. *Biochem J* 438, e5–6 (2011).

21. North, R. J., Neubauer, R. H., Huang, J. J., Newton, R. C. & Loveless, S. E. Interleukin 1-induced, T cell-mediated regulation of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. *J Exp Med* 168, 2031–2043 (1988).

22. Haabth, O. A., Bogen, B. & Corhay, A. A model for cancer-suppressive inflammation. *Oncoimmunology* 1, 1146–1155 (2012).

23. Durfourt, T. et al. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model. *PLoS One* 7, e29213 (2012).

24. Scheu, S. et al. Activation of the integrated stress response during T helper cell differentiation. *Nature immunology* 7, 644–651 (2006).

25. Kohn, A. D., Summers, S. A., Birnbaum, M. J. & Roth, R. A. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. *J Biol Chem* 271, 31372–31378 (1996).

26. Elstrom, R. L. et al. Akt stimulates aerobic glycolysis in cancer cells. *Cancer Res* 64, 3892–3899 (2004).

27. Robey, R. B. & Hay, N. Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. *Seminars in cancer biology* 19, 25–31 (2009).

28. Sukumar, M. et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. *J Clin Invest* 123, 4479–4488 (2013).

29. Kline, E. E. et al. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. *The Journal of urology* 176, 2274–2279 (2006).

30. Giskeodgaard, G. F. et al. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. *PLoS One* 8, e62375 (2013).

31. Xie, H. et al. Targeting lactate dehydrogenase–a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. *Cell Metab* 19, 795–809 (2014).

32. Fujii, T., Khawaja, M. R., DiNardo, C. D., Atkins, J. T. & Janku, F. Targeting isocitrate dehydrogenase (IDH) in cancer. *Discov Med* 21, 373–380 (2016).

33. Nath, S. & Mukherjee, P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. *Trends Mol Med* 20, 332–342 (2014).

34. Singh, R. & Bandypadhyay, D. MUC1: a target molecule for cancer therapy. *Cancer Biol Ther* 6, 481–486 (2007).

35. Smith, T. J. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? *Pharmacological reviews* 62, 199–236 (2010).

36. Pollak, M. Insulin-like growth factors and neoplasia. *Best practice & research. Clinical endocrinology & metabolism* 22, 625–638 (2008).

37. Pollak, M. Targeting insulin and insulin-like growth factor signalling in oncology. *Current opinion in pharmacology* 8, 384–392 (2008).

38. Gong, Y. et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). *PLoS One* 4, e7273 (2009).

39. Litzenburger, B. C. et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumours correlates with sensitivity to anti-IGF-IR therapy. *Clin Cancer Res* 17, 2314–2327 (2011).

40. Resnik, J. L., Reichart, D. B., Huey, K., Webster, N. J. & Seely, B. L. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. *Cancer Res* 58, 1159–1164 (1998).

41. Balachandran, S. et al. Phase I dose-escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. *Clin Cancer Res* 13, 5834–5840 (2007).

42. Karp, D. D. et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. *J Clin Oncol* 27, 2516–2522 (2009).

43. Luo, H. et al. PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. *Cell Death Dis* 4, e841 (2013).

44. Mounir, Z. et al. Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway. *Sci Signal* 2, ra85 (2009).

45. Balachandran, S. & Barber, G. N. PKR in innate immunity, cancer, and viral oncolysis. *Methods Mol Biol* 383, 277–301 (2007).
46. Numata, K. et al. Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1. *J Cancer Res Clin Oncol* **142**, 415–422 (2016).
47. Gryko, M. et al. Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. *Pol J Pathol* **65**, 135–140 (2014).
48. Jain, P., Jain, P., Tandon, H. C. & Babbar, R. Effect of sodium citrate ingestion on oxygen debt & exercise endurance during supramaximal exercise. *Indian J Med Res* **118**, 42–46 (2003).
49. Cox, G. & Jenkims, D. G. The physiological and ventilatory responses to repeated 60 s sprints following sodium citrate ingestion. *J Sports Sci* **12**, 469–475 (1994).
50. Hanai, I., Doro, N., Seth, P. & Sukhatme, V. P. ATP citrate lyase knockdown impacts cancer stem cells *in vitro*. *Cell Death Dis* **4**, e696 (2013).
51. Ren, J. G., Li, Z. & Sacks, D. B. IQGAP1 modulates activation of B-Raf. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 10465–10469 (2007).
52. Benson, J. D. et al. Validating cancer drug targets. *Nature* **441**, 451–456 (2006).
53. Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. *Cancer cell* **10**, 241–252 (2006).
54. Verrax, J., Stocks, J., Tison, A., Taper, H. S. & Calderon, P. B. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. *Biochemical pharmacology* **72**, 671–680 (2006).
55. Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. *Genes Dev* **15**, 3249–3262 (2001).
56. Moody, S. E. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. *Cancer cell* **2**, 451–461 (2002).
57. Ren, J. G., Seth, P., Everett, P., Clish, C. B. & Sukhatme, V. P. Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. *PLoS One* **5** (2010).
58. Ren, J. G. et al. Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling. *Sci Rep* **4**, 5414 (2014).

Acknowledgements
We thank Dr. Lewis Chodosh (University of Pennsylvania) for kindly providing us the Her2/Neu mice. Part of this research was supported by seed funds from BIDMC.

Author Contributions
J.G.R. and V.P.S. designed the experiments. J.G.R., P.S., H.Y., K.G., J.H., and Z.H. carried out the experiments and calculations. J.G.R. and V.P.S. wrote the main manuscript text and J.G.R. prepared all of the Figures. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-04626-4

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017